XML 81 R73.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segments - Schedule of Drug Development Segment and Reconciliation to Consolidated Net (Loss) Income Segment Operations (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Total revenue $ 3,746 $ 140,141
Clinical expense 8,085 15,452
Chemistry, manufacturing, and controls 7,161 3,273
Preclinical expense 2,420 1,740
Selling, general and administrative 14,458 20,920
Income tax expense 151 138
Interest expense 828 3,130
Interest income 4,291 3,954
Other segment (income) expense [1] (3,778) 32,401
Segment net (loss) income (21,288) 67,041
Net (loss) income (21,288) 67,041
Adjustments and reconciling items $ 0 $ 0
[1] Other segment (income) expense includes other research and development expense, amortization of debt issuance costs and discount, other income, warrant liabilities fair value adjustment, derivative liability fair value adjustment, and cost of product revenue.